Jeevan Scientific Technology Reports Strong Profit Turnaround in Q1 FY27

Jeevan Scientific Technology posted a net profit of Rs 1.89 crore for the quarter ended June 30, 2026, a significant improvement from a net loss of Rs 2.16 crore in the same quarter last year.

Reader Takeaway: Profitability turnaround driven by revenue growth; subsidiary Nayas Laboratories reports a net loss.

What just happened

Jeevan Scientific Technology Ltd. has announced its financial results for the first quarter of fiscal year 2027 (Q1 FY27). The company reported a net profit of Rs 1.89 crore on a standalone basis, a stark contrast to the net loss of Rs 2.16 crore in Q1 FY26. Standalone revenue from operations more than doubled to Rs 16.93 crore from Rs 8.22 crore year-on-year.

Consolidated figures also show a positive shift, with a net profit of Rs 0.87 crore in Q1 FY27, compared to a consolidated net loss of Rs 1.26 crore in Q1 FY26. Consolidated revenue from operations grew to Rs 18.28 crore from Rs 10.06 crore.

Why this matters

The shift from loss to profit is a critical indicator of improved financial health and operational efficiency. This turnaround can instill investor confidence and potentially drive stock performance, provided it is sustainable.

The backstory

Jeevan Scientific Technology operates in the clinical research services space. The company's subsidiary, Nayas Laboratories Private Limited, incurred a net loss of Rs 1.01 crore during the quarter.

What changes now

The company has also announced board and leadership changes, subject to shareholder approval. These include re-appointments of Whole Time Directors and Independent Directors, and the appointment of a new Additional and Independent Director. The Annual General Meeting for FY 2025-26 is scheduled for September 25, 2026.

Risks to watch

The net loss reported by the subsidiary, Nayas Laboratories Private Limited, for Q1 FY27, despite the parent company's profitability, warrants attention. Investors should closely monitor the performance and financial health of subsidiaries.

Peer comparison

(Information not available in the filing)

Context metrics (time-bound)

• Q1 FY27 Standalone Net Profit: Rs 1.89 crore (vs. Rs -2.16 crore in Q1 FY26)
• Q1 FY27 Consolidated Net Profit: Rs 0.87 crore (vs. Rs -1.26 crore in Q1 FY26)
• Q1 FY27 Standalone Revenue: Rs 16.93 crore (vs. Rs 8.22 crore in Q1 FY26)
• Q1 FY27 Consolidated Revenue: Rs 18.28 crore (vs. Rs 10.06 crore in Q1 FY26)

What to track next

Investors should watch for sustained profitability in the upcoming quarters and the performance of Nayas Laboratories. The approved board changes and their effectiveness will also be crucial.